Watching the interesting FY 2022 company presentation on YouTube "Investor Meet Company" this afternoon when it was suddenly taken down - apparently withdrawn "This video has been removed by the uploader".
Does anyone know why?
Is the presentation available on any other platform?
Was there some "inside" information disclosed? |
 Todays RNS in my view is close to delusional and in no way reflects the objective state of the business. That said despite all the puffery the chairman did manage to slip in "2023 will see a short-term contraction in revenues" ..... so did 2022.
So they know 2023 is going to be worse than 2022. So lets review the STRONG 2022
Revenue - Down
Gross Profit - Down
Gross Margin - Down
EBITDA - Down
Operating Profit - Down
Profit Per Share - Down
Order Book - Down
Cash - Down
Net Assets - Up (because the capitalised some GBP 2.3 million of development costs, without this capitalisation the company would have reported a loss in excess of GBP 1 million)
They have also admitted, as I have highlighted before that in order to pick up any significant work in Alzheimer's they need to make additional investment and that will only pay off over an extended time period, as any clinical program that is already in flight will not switch providers or approach. The resulting nature of this you are filling the funnel with low value Phase I trails at this time.
They need to win one but prefferably two very large contracts and very soon if they are have chance of avoiding an additional and significant fall in the share price.
Without this happening in the next 6 months and using the maxim that it is better to raise when you can than when you have to a chunky CR in the second half of next year is likely. |
Strong transformation with improvements in all areas beating expectations. Now we are set for a steady increase with some huge contracts in the pipeline. 2023 looking strong and with 70p target worth topping up at these levels. Some say 95p target.. |
Unless they sign some very large contracts, very soon they are going to bleed cash in 2023. Based on the trading update at GBP 8.6 million revenue and GBP 1.5 million they were cashflow negative to the tune of GBP 900k. Revenue for FY 2023 is forecast to fall to 7 million.
For what its worth the Chief Commercial Officer hire from 2.5 years ago, Lammert Albers, who was considered an important enough hire to RNS and to roll out on Proactive Investors, quit during the summer.
If the boards and senior executive team are not shaken up soon this will be taken out and for a lot less than its intrinsic worth. |
Fathoms, I agree but sales are ramping up and new customers are seeing the value in the solution. American companies increases interest in IXICO. Their technology application does set them apart. American Takeover gets more likely with strong Dollar. Watch this space… |
@halfpenny - I think you might be right about a takeover.
Even-though the business will not grow revenue in FY2023 and probably not in FY2024 and it also has a neutral book to bill ratio, it could be made instantly profitable on a go forward basis by stripping out the listing costs and replacing the c suite, who are possibly the most overpaid team in the microcap AIM space. The compensation of the CEO, CFO and CBO, for no progress over the last three years, borders on the obscene.
I strongly suspect a bid below 50p would be successful, however still profitable for you given you recent entry point. |
IXI chart looking strong with Higher Highs and Higher lows. Extremely positive so I expect once 60p breaks then its Happy times ahead. The 100p and above can be achieved with a Takeover offer which may also be in the pipeline with the Dollar being High...Interesting times ahead for IXI.... |
IXI looks like a strong takeover target at these levels. IXI results show its great future with high demand for their products and services. The next generation product is evolving so future is bright. Adding more getting ready for liftoff soon with RNS release. |
The management have delivered, well done. With improved sales, software and demand increasing IXI have a strong future. Just added and looking forward to future contract wins. Wot a turnaround by the management team. |
Very positive update.
Interesting company.
hmmm |
Eh oop la - signs of life? |
The management is justifying its share price by talking about P/S ratios.. i think they should focus on the business.. the stock price will take care of itself.. this product doesn't seem to be as mission critical as the management is portraying it to be.. |
Wot a turnaround well done!! |
40p+ coming - |
I wonder what CFE's plans for CIP Merchant Capital are now the takeover is a done deal? Will they liquidate all the assets for a profit? If so there is going to be a lot of IXICO stock available at some point sooner or later. I guess if that is the case the price is going nowhere for a while but we'll see. |
This truly is a great little company......... If you're a director
Nice lifestyle.
Unfortunately the business is niche, focused on rare conditions and not broader applications.
Maybe a takeover target at some point, the chart says it all. |
NT at 38p -
Good 800k contract - |
IXICO plc New Contract Win
21/04/2022 7:00am
UK Regulatory (RNS & others)
Ixico (LSE:IXI)
Intraday Stock Chart
Thursday 21 April 2022
Click Here for more Ixico Charts.
TIDMIXI
RNS Number : 8126I
IXICO plc
21 April 2022
21 April 2022
IXICO plc
("IXICO" or the "Company")
Contract award with a new client for a Huntington's Disease ('HD') trial worth circa GBP800,000
IXICO plc (AIM: IXI), the neuroimaging Contract Research Organisation (CRO) delivering advanced AI analytical insights in neuroscience, is pleased to announce it has been selected by a new client to support its global prospective observational study to assess participants for the early detection of HD. HD is a rare, inherited disease that causes the progressive breakdown of nerve cells in the brain affecting movement, mood and thinking abilities.
The new client is a biotech company specialized in gene therapy for neurodegenerative and other genetic diseases. IXICO will provide a range of its imaging CRO and advanced analytics services across approximately 2.5 years.
Having combined AI imaging biomarker analysis across many HD trials, together with centralised CRO services, IXICO is continuously enhancing its validated disease-optimised advanced analytics technology for this indication. This new contract follows our recent presentation on our new deep learning-based platform, IXIQ.Ai, at the Annual HD Therapeutics Conference in Palm Springs, a technology which IXICO will be applying to this trial. This, together with the ability to deliver its services through our proprietary TrialTracker imaging data management platform, makes IXICO the clear partner of choice for this study.
Giulio Cerroni, Chief Executive Officer of IXICO, commented : " With no current cure for Huntington's, nor interventions that slow disease progression, HD is a devastating rare neurological condition with significant unmet medical needs. We are delighted to further extend our client base and support identifying new insights into this challenging rare neurodegenerative disease. We are committed to ensuring that our validated machine learning AI data analytics, combined with the quality assurance of our TrialTracker platform, enable clients to unlock new insights into disease progression and drug development."
For further information please contact: |
Rising from 52 weeks lows - |
Interesting IXI target Takeover soon. |
...from last year...
Company overview:
Ixico plc provides neuroscience expertise, analysis and global operational support for CNS clinical trials. As a result, we could easily put it into the technology sector, as their specialist neuroscience knowledge and AI-driven innovation provides solutions for sponsors to realize the full power of imaging biomarkers. Their scans observe small changes in brain structure, provide insights on the efficacy of new drugs trialled and monitor patient safety. They are estimating a £120m-£150m addressable imaging market per annum and currently have above 10% of market share. In addition, the ageing population of the planet would mean the CNS market will expand, with preliminary forecasts of triple increase of dementia cases across the world between 2015 and 2050 (coming from the World Alzheimer report in 2018).
Growth is organic, with virtually zero acquisitions over the past 10 years. IXI is continuously investing in R&D and revenue is seeing a healthy 25% CAGR, and the company has become profitable in 2019. They are sitting on a pile of cash, as the company is debt free and return on capital and on equity are both in the top 10 of the industry.
Lates trading update is the yearly just before the full period results. Things are looking good for this year. They have generated £9.2m of revenue, which is ahead of market expectations (£8.7m). EBITDA is also expected to be ahead of the consensus £1.2m. In addition, they have a strong order book of £18.8m they are, however, balancing the positives with a more neutral expectation for the upcoming FY, where they are expecting a return to more normal growth rates, meaning they forecast lower earnings for 2022. We cannot wait for the yearly results on this one, as trading has been strong this year. Although P/E is high at around 31 on TTM basis if they deliver good profitability the stock might prove to be a good investment in the long-run as they are operating in one of the most crucial for our evolvement industries....
...from WealthOracleAM |
It would only be useful on a car that keeps backfiring |
Would anyone on here be interested in the car reg no IXI 4060?
DC |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
